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Migraine is thought to be triggered by excessive neocortical neuronal excitability that leads to cortical
spreading depression. In this issue of Neuron, Tottene et al. study a mouse model of familial hemiplegic
migraine type 1, and provide evidence for the hyperactivity of P/Q-type calcium channel-mediated cortical
glutamatergic synaptic transmission as an underlying mechanism for the susceptibility of cortical spreading
depression initiation in migraine disorders.Neuronexperiment linking the enhancement of
P/Q-type calcium channel function to the
facilitation of CSD. They show that appli-
cation of a subsaturating concentration
of u-AgaIVA (a specific P/Q-type calcium
channel blocker) that reduces glutamate
release at mutant synapses to the levels
ofwild-type synapsescompletely restores
the facilitation of CSD induction and prop-
agation in cortical slices from the mutant
mice.
In addition to the frank upregulation of
excitatory transmission by the R192Q
mutation, other mechanisms may also
contribute to the hyperactivity of cortical
circuits. The increased P/Q-type calcium
current results in a relative shift in the
dependence of neurotransmission on
P/Q-, N- and R-type calcium channels
toward P/Q-type channels. This shift in
the presynaptic calcium entry pathway
could decrease G protein inhibition of
neurotransmitter release because P/Q-
type channels undergo less modulation
than N-type channels (Zamponi, 2001).
For instance, during cortical activity acti-
vation of presynaptic GABAB receptors
at excitatory synapses may cause less
inhibition of glutamate release in R192Q
mutant mice, leading to more excitation
of neural network.
The findings of Tottene and colleagues
contribute novel insights into our under-
standing of the cellular and synaptic
mechanisms of CSD and migraine, and
highlight how good basic science
research may point out the direction in
which to search for novel therapies.Mean-
while, these exciting results also raise
several interesting and even puzzling
questions for future studies. The firsta knockin mouse model of FHM1, the
mutant mice show increased P/Q-type
calcium current density in cerebellar
granule cells and enhanced neurotrans-
mitter release at neuromuscular junctions
(Kaja et al., 2005; van den Maagdenberg
et al., 2004). More importantly, the
R192Qmutant mice show reduced induc-
tion threshold and increased velocity of
CSD (van den Maagdenberg et al., 2004),
but how this gain-of-function mutation
contributes to thevulnerability ofCSD initi-
ation in migraine remained unclear.
Tottene et al. (2009) now take advan-
tage of autaptic cortical cultures to clearly
show an enhanced excitatory synaptic
transmission in R192Q mutant mice, and
demonstrate that this enhancement is
due to a specific enhancement of P/Q-
type calcium current and an increase in
release probability without alteration of
other synaptic parameters. This conclu-
sion is further strengthened by paired
recordings of layer 2/3 pyramidal cells
and fast-spiking interneurons in acute
cortical slices, in which Tottene et al.
show that glutamatergic connections,
but surprisingly not GABAergic connec-
tions, are enhanced in mutant mice.
These results allow the authors to
develop a plausible model in which
specific enhancement of excitatory drive
by R192Q mutation in Cav2.1 alters the
balance between excitation and inhibition
during cortical activity, which in turn facil-
itates the induction and propagation of
CSD. Although Tottene et al. (2009) do
not directly show that the excitatory inputs
onto pyramidal cells are increased and
pyramidal cells are therefore hyperactive,
they do present a convincing and elegantMigraine is a common neurological
syndrome characterized by episodic
disablingheadachepain that isoftenasso-
ciatedwithaprecedingaura (migrainewith
aura). Functional neuroimaging studies
observe cortical hemodynamic changes
in migraine with aura patients that
resemble those observed during cortical
spreading depression (CSD), indicating
that CSD may cause migraine aura and
trigger migraine headache (Sanchez del
Rio and Alvarez Linera, 2004). CSD is
a wave of neuronal excitation that slowly
propagates across the cortex, causing
brief intense spike trains followed by
long-lasting suppression of neuronal
activities (Smith et al., 2006). Are these
waves causal for migraine and how are
they generated in the first place? Tottene
et al. (2009) in this issue ofNeuron provide
evidence that a potentiation of glutamate
releasemay alter the excitation and inhibi-
tion balance in neuronal networks that
could contribute to the vulnerability of
CSD initiation in migraine disorders.
Familial hemiplegic migraine type 1
(FHM1), a rare autosomal dominant
subtype of migraine with aura, is caused
by a series of missense mutations in
CACNA1A gene that encodes the pore-
forming subunit (a1 subunit) of voltage-
gated P/Q-type (Cav2.1) calcium channel
(Ophoff et al., 1996). It seems very likely
that FHM1 mutations may alter synaptic
transmission because of the prominent
location of these channels at the presyn-
aptic termini and their crucial role in
controlling neurotransmitter release.
Indeed, when one of these mutations
(R192Q) was introduced into the mouse-
endogenous cacna1a gene to create61, March 12, 2009 ª2009 Elsevier Inc. 653
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whether the R192Q mutant mice actually
exhibit ‘‘migraine,’’ or whether the trigem-
inal nociception is altered in these mice.
So far no behavioral abnormalities in these
mice have been reported, but it will be
muchmoreuseful for therapeutic interven-
tion to identify behavioral migraine pheno-
types in this FHM1 model. It will be also
interesting to examine the cellular and
behavioral phenotypes in the R192Q
heterozygousmice since FHM1 is a domi-
nant inherited disorder.
Both loss-of-function and gain-of-
function phenotypes in P/Q-type calcium
channel function and synaptic signaling
have been reported for the FHM1 muta-
tions in various experimental conditions
(Barrett et al., 2005; Cao et al., 2004; Cao
and Tsien, 2005; Hans et al., 1999; Kraus
et al., 1998; Tottene et al., 2002, 2009;
vandenMaagdenberg et al., 2004). Partic-
ularly, rescue experiments using a human
Cav2.1 splice variant in hippocampal
neurons from cacna1a knockout mice
show that several FHM1 mutations
including R192Q decrease P/Q-type
calcium current and its contribution to
neurotransmitter release. However, the
overall synaptic strength is well main-
tained because N-type calcium channels
compensate for the defective P/Q-type
calcium channels (Cao et al., 2004; Cao
and Tsien, 2005). One should not take
this controversy lightly because the exact
functional consequences of these muta-
tions will determine the directions in which
we should look for the potential therapies.
Onepossibility suggestedby Tottene et al.
(2009) is that although R192Q mutation
induces gain-of-function changes in
Cav2.1 function, insufficient surface
expression of mutant Cav2.1 in trans-
fected neurons leads to apparent loss-
of-function phenotypes. However, this
explanation cannot readily account for
the dominant-negative effect of R192Q
when it is overexpressed in wild-type
neurons (Cao et al., 2004; Cao and Tsien,
2005). Another possible explanation
suggested by Cao and colleagues is the
difference between species of Cav2.1
used in different studies because, for
example, Cav2.1 of rabbit and human are
differentially affected by FHM1 mutations
and trinucleotide expansions that cause654 Neuron 61, March 12, 2009 ª2009 Elsevspinocerebellar ataxia type 6 (Cao et al.,
2004). It should be straightforward to test
this idea by comparing wild-type and
mutant Cav2.1 from different species in
cacna1a knockout neurons. Regardless
of the outcome of this comparison, the
ultimate question is what happens in
FHM1 patients and what is a good model
for FHM1. A subgroup of migraineurs
with aura exhibits abnormal neuromus-
cular transmission, supporting the loss-
of-function in P/Q-type calcium channel
model (Ambrosini et al., 2001), but it is
not clear whether these patients carry
FHM1mutations. In fact, abnormal neuro-
muscular transmission is not detected in
some FHM1 patients (Terwindt et al.,
2004). In this context, whether the R192Q
mutant mice display migraine is vital for
future research. Additional transgenic
mice carrying other FHM1 mutations will
also be helpful and valuable for reconciling
the controversy, understanding themech-
anism of migraine, and testing potential
therapeutic strategies.
Another intriguing observation that
Tottene and colleagues made in this study
is that the R192Q mutation does not affect
synaptic transmission at the GABAergic
synapses from fast-spiking interneurons
to pyramidal cells, even though P/Q-type
calcium currents exclusively mediate
neurotransmitter releaseat thesesynapses
(Tottene et al., 2009). Is it possible that at
these synapses, the P/Q-type calcium
currents evoked by action potentials are
barely affected by the R192Q mutation?
Could it be that a different set of calcium
channel auxiliary subunits, channel-asso-
ciated proteins, or both is expressed in
fast-spiking interneurons that somehow
modulate channel function so that the
effect of R192Q mutation is minimal? This
finding also poses a challenge to future
drug discovery of how to selectively target
affected glutamatergic synapses without
compromising normal synapses. What
about the effects of R192Q mutation on
other inhibitory and modulatory synapses
and their impactson theexcitationand inhi-
bition balance in cortical circuits? It will not
be surprising to see differential effects of
R192Q mutation at different synapses
given the great diversity of cell types in
the brain, specially the GABAergic inter-
neurons. In fact, Tottene et al. (2009)ier Inc.already observe a difference in the activa-
tion properties of Cav2.1 between cere-
bellar granule cells and cortical pyramidal
cells, indicating a diversity of P/Q-type
calcium channels. A better appreciation of
this diversity at the molecular level will not
only further our understanding of calcium
channels in general, but also certainly aid
the discovery of therapeutic approaches
for calcium channelopathies.
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